Foldink
A biotechnology startup that develops modular 3D bioprinters and customizable bioinks to democratize tissue engineering and regenerative medicine research.
- CEO / Founder
- Emmanuel Ghandilyan
- Team Size
- 10-50
- Stage
- Active
- Total Funding
- $200K
- Latest Round
- Seed
- Key Investors
- FAST (Foundation for Armenian Science and Technology); Ventures Thrive (EU); Ministry of High-Tech Industry of Armenia; Gevork Sarkisyan (strategic investor and board member); Tigran Oganesov (strategic advisor and investor)
Technology & Products
Key Products
["Modular 3D Bioprinters (Syringe-based microextrusion systems)","Customizable Bioinks (GelMA, Alginate-based, and freeze-dried hydrogels)","X-TRUDR4™ Printheads","Bioprinting Accessories (LAP and Irgacure Photoinitiators)","Custom Tissue Engineering and Scaffold Fabrication Services"]
Technological Advantage
Proprietary syringe-based microextrusion technology optimized for high cell viability and precision; specialized bioink formulations that support diverse cell types and tissue models.
Differentiation
Value Proposition
Lowering the cost and technical barriers of 3D bioprinting through modular, affordable hardware and high-performance biomaterials, making advanced tissue engineering accessible to every laboratory.
How They Differentiate
Foldink differentiates through a modular 'build-your-own' bioprinter approach and high-performance bioinks that eliminate batch-to-batch variability. Their value proposition centers on a superior quality-to-price ratio, making advanced tissue engineering accessible to smaller research labs that are priced out by high-end competitors.
Market & Competition
Target Customers
Biomedical researchers, academic institutions, pharmaceutical R&D departments, and biotechnological research centers.
Industry Verticals
["Biotechnology","Healthcare","Pharmaceuticals","Regenerative Medicine","Cancer Research"]
Competitors
["CELLINK (BICO)","Allevi (3D Systems)","Aspect Biosystems","RegenHU"]
Growth & Milestones
Growth Metrics
Reported first commercial sales in 2022; expanded from a university research project to a commercial entity with international distribution of bioinks and modular printheads.
Major Milestones
["Founded in 2018 as a research project at Yerevan State Medical University","Incorporated as a full-fledged company in 2019","Winner of the STEP (Science and Technology Entrepreneurship Program) competition in 2021","Achieved first commercial sales of bioprinting products in 2022","Selected for the Ventures Thrive EU deep-tech acceleration program in 2023","Established Foldink Corp in Frisco, Texas to manage North American operations"]
Notable Customers
["Yerevan State Medical University (YSMU)","Institute of Molecular Biology of NAS RA","Various European research laboratories"]